Phase III Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01)
This Funding Opportunity Announcement (FOA) encourages R01 grant applications that propose to develop and implement Phase III clinical trials of promising pharmacological and non-pharmacological interventions in individuals with age-related cognitive decline and across the Alzheimer's disease (AD) spectrum from pre-symptomatic to more severe stages of disease.
General information about this opportunity
Last Known Status
Active
Program Number
PAR-16-364 Federal Agency/Office
Agency: Department of Health and Human ServicesOffice: National Institutes of Health
Type(s) of Assistance Offered
Grant Who is eligible to apply/benefit from this assistance?
Applicant Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. What is the process for applying and being award this assistance?
Deadlines
09/07/2018 Other Assistance Considerations
Formula and Matching Requirements
This program does not have cost sharing or matching requirements. Who do I contact about this opportunity?
Headquarters Office
NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
Website Address
http://grants.nih.gov/grants/guide/pa-files/PAR-16-364.html
E-mail Address
FBOWebmaster@OD.NIH.GOV
Financial Information
Obligations
$25,000,000.00
